MCID: PYD001
MIFTS: 55

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pyoderma Gangrenosum

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 11 19 58 75 53 43 14 16 71 31 33
Phagedenic Pyoderma 33
Phagedena Geometric 33

Characteristics:


Prevelance:

1-9/100000 (United States) 1-9/1000000 (United Kingdom, Spain, Worldwide, Italy) 58

Age Of Onset:

Adolescent,Adult,Childhood,Elderly 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 11 DOID:8553
ICD9CM 34 686.01
MeSH 43 D017511
SNOMED-CT 68 74578003
ICD10 31 L88
MESH via Orphanet 44 D017511
ICD10 via Orphanet 32 L88
UMLS via Orphanet 72 C0085652
Orphanet 58 ORPHA48104
ICD11 33 2120746218
UMLS 71 C0085652

Summaries for Pyoderma Gangrenosum

GARD: 19 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, Pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with Pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy.

MalaCards based summary: Pyoderma Gangrenosum, also known as phagedenic pyoderma, is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and neutrophilic dermatosis, acute febrile. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Integrin Pathway. The drugs Anti-Inflammatory Agents and Endothelial Growth Factors have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and myeloid, and related phenotypes are fever and skin ulcer

Orphanet: 58 Pyoderma gangrenosum (PG) is a primarily sterile inflammatory neutrophilic dermatosis characterized by recurrent cutaneous ulcerations with a mucopurulent or hemorrhagic exudate.

Wikipedia: 75 Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 827)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 33.1 PSTPIP1 NLRP3 MVK MEFV
2 neutrophilic dermatosis, acute febrile 31.9 TNF SIGLEC5 PSTPIP1 MEFV CXCL8 CSF3
3 inflammatory bowel disease 1 31.8 TNF NOD2 CCR6
4 crohn's disease 31.5 TNF SIGLEC5 NOD2 NLRP3 CXCL8 CCR6
5 ulcerative colitis 31.5 TNF NOD2 IL1R1 CXCL8 CCR6
6 fasciitis 31.4 TNF MMP1 CXCL8
7 necrotizing fasciitis 31.4 TNF F3 CXCL8
8 erythema nodosum 31.3 TNF NOD2 CXCL8
9 hidradenitis suppurativa 31.3 TNF PSTPIP1 NOD2 NLRP3 MEFV
10 hidradenitis 31.3 TNF PSTPIP1 NOD2 NLRP3 MEFV
11 vasculitis 31.3 TNF MEFV ITGB2 IFNA2 CXCL8 APOH
12 myelofibrosis 31.2 TNF IFNA2 CXCL8 CSF3
13 acne 31.1 TNF PSTPIP1 NLRP3 MMP1 MEFV CXCL8
14 colitis 31.1 TNF NOD2 IL1R1 CXCL8 CHI3L1 CCR6
15 erythema elevatum diutinum 31.0 PSTPIP1 CXCL8
16 myelodysplastic syndrome 31.0 TNF IFNA2 CXCL8 CSF3 CCR6
17 hypersensitivity vasculitis 31.0 TNF MEFV CCR6
18 polyarteritis nodosa 31.0 TNF MEFV ITGB2 IFNA2 APOH
19 polycythemia vera 30.9 TNF IFNA2 F3 CSF3
20 spondyloarthropathy 1 30.9 TNF NOD2 IL1R1 CCR6
21 pouchitis 30.9 TNF NOD2
22 antiphospholipid syndrome 30.9 TNF F3 APOH
23 purpura 30.8 TNF F3 CXCL8 APOH
24 granulomatous dermatitis 30.8 TNF NOD2
25 cholangitis 30.8 TNF NOD2 F3 CXCL8
26 diverticulitis 30.7 TNF MMP9 CCR6
27 chronic recurrent multifocal osteomyelitis 30.7 TNF PSTPIP1 NOD2 NLRP3 MEFV
28 enterocolitis 30.7 TNF NOD2 CXCL8
29 neutropenia 30.7 TNF IFNA2 CXCL8 CSF3
30 decubitus ulcer 30.7 TNF MMP9 CXCL8
31 aortitis 30.7 TNF CSF3 CCR6
32 autoimmune disease 30.6 TNF MMP9 F3 CCR6 APOH
33 scleritis 30.6 TNF MMP9 ITGB2 CCR6
34 synovitis 30.6 TNF MMP9 MMP1 CXCL8
35 erysipelas 30.6 TNF PSTPIP1 MVK MEFV
36 fungal infectious disease 30.6 TNF CXCL8 CSF3 CCR6
37 cholangitis, primary sclerosing 30.6 TNF NOD2 CXCL8 CCR6
38 toxic shock syndrome 30.6 TNF IL1R1 F3 CXCL8 CSF3
39 cyclic neutropenia 30.6 TNF CXCL8 CSF3
40 chronic ulcer of skin 30.6 TNF MMP9 MMP1 CXCL8
41 osteomyelitis 30.5 TNF NOD2 NLRP3 MMP1 MEFV CXCL8
42 psoriasis 30.5 TNF NOD2 ITGB2 IL1R1 CXCL8 CCR6
43 diarrhea 30.5 TNF NOD2 MVK IFNA2 CXCL8 CSF3
44 sarcoidosis 1 30.5 TNF NOD2 CHI3L1 CCR6
45 spondylitis 30.5 TNF NOD2 CHI3L1 CCR6
46 deficiency anemia 30.5 TNF IFNA2 F3 CSF3 CCR6
47 autoinflammatory syndrome 30.5 NOD2 NLRP3 MVK MEFV
48 mucormycosis 30.5 TNF CSF3 CCR6
49 hepatitis a 30.5 TNF IFNA2 F3
50 inguinal hernia 30.5 MMP9 MMP1 F3

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

58 30 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001945
2 skin ulcer 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200042
3 arthralgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002829
4 myalgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003326
5 papule 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0200034
6 myositis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100614
7 inflammation of the large intestine 58 30 Frequent (33%) Frequent (79-30%)
HP:0002037
8 myelodysplasia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002863
9 pustule 58 30 Frequent (33%) Frequent (79-30%)
HP:0200039
10 atrophic scars 58 30 Frequent (33%) Frequent (79-30%)
HP:0001075
11 rheumatoid arthritis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001370
12 myeloid leukemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0012324
13 increased circulating antibody level 30 Frequent (33%) HP:0010702
14 skin vesicle 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200037
15 abnormal blistering of the skin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008066
16 increased antibody level in blood 58 Frequent (79-30%)

GenomeRNAi Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 APOH CCR6 CHI3L1 CSF3 CXCL8 F3
2 no effect GR00402-S-2 10.19 APOH CCR6 CHI3L1 CSF3 F3 IFNA2

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.86 CCR6 CHI3L1 CSF3 F3 IFNA2 IL1R1
2 hematopoietic system MP:0005397 9.47 CCR6 CHI3L1 CSF3 F3 IFNA2 IL1R1

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Inflammatory Agents Phase 4
2 Endothelial Growth Factors Phase 4
3 Mitogens Phase 4
4
Adalimumab Approved, Experimental Phase 3 331731-18-1
5 Antirheumatic Agents Phase 3
6 Pharmaceutical Solutions Phase 3
7
Ixekizumab Approved, Investigational Phase 2 1143503-69-8
8
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
9
Vilobelimab Investigational Phase 2 2250440-41-4
10 Dermatologic Agents Phase 2
11 Complement System Proteins Phase 2
12 Immunosuppressive Agents Phase 2
13
Infliximab Approved 170277-31-3
14
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical 133585-56-5, 60-18-4, 556-02-5 1153 6057
15 Gastrointestinal Agents
16 Immunoglobulins, Intravenous Early Phase 1
17 Antineoplastic Agents, Immunological Early Phase 1

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Novel Therapeutic Treatment of Pyoderma Gangrenosum Recruiting NCT05120726 Phase 4
2 A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan Completed NCT03311464 Phase 3 adalimumab
3 Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum As a New Treatment Strategy Not yet recruiting NCT05343754 Phase 3 Hyperbaric oxygen
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
6 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
7 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Unknown status NCT02733094 Phase 1, Phase 2 Secukinumab
8 An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
9 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
10 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
11 Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima) Completed NCT03971643 Phase 2 IFX-1
12 A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
13 Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Recruiting NCT04901325 Phase 2 Baricitinib
14 A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
15 The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum Withdrawn NCT04274166 Phase 2 secukinumab 150 mg (2 injections per dose
16 A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) Withdrawn NCT00690846 Phase 2 adalimumab
17 Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira
18 Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015 Unknown status NCT03636737
19 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Unknown status NCT01952275
20 An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum Completed NCT00791557 Infliximab
21 Post-marketing Observational Study for Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) Recruiting NCT04750213
22 Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma Active, not recruiting NCT04895566 Early Phase 1
23 Expression of the JAK-STAT Signaling Pathway in Pyoderma Gangrenosum Pathological Biopsy Not yet recruiting NCT04792957

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clofazimine
SULFAPYRIDINE PWDR

Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

Anatomical Context for Pyoderma Gangrenosum

Organs/tissues related to Pyoderma Gangrenosum:

MalaCards : Skin, Bone, Myeloid, Neutrophil, Breast, Endothelial, Spleen

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 3577)
# Title Authors PMID Year
1
Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. 53 62
19700023 2009
2
Pyrin Modulates the Intracellular Distribution of PSTPIP1. 53 62
19584923 2009
3
PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. 53 62
19290936 2009
4
The inherited autoinflammatory syndrome: a decade of discovery. 53 62
19768193 2009
5
Autoinflammatory diseases: clinical and genetic advances. 53 62
18347298 2008
6
Autoinflammatory gene mutations in Behçet's disease. 53 62
17213252 2007
7
The systemic autoinflammatory diseases: inborn errors of the innate immune system. 53 62
16724804 2006
8
Autoinflammatory syndromes. 53 62
16466630 2006
9
Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. 53 62
15916580 2005
10
A common pathway in periodic fever syndromes. 53 62
15324736 2004
11
CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. 53 62
15102098 2004
12
Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. 62
35599359 2022
13
Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine. 62
35771124 2022
14
[Clinical analysis of 49 cases of non-inflammasome related conditions]. 62
36444428 2022
15
Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database. 62
35933497 2022
16
Neutrophilic dermatoses. 62
35870984 2022
17
Successful treatment of pyoderma gangrenosum using adalimumab in a patient undergoing hemodialysis. 62
35862244 2022
18
A Case of Post-caesarean Pyoderma Gangrenosum. 62
36457428 2022
19
Improvement of refractory pyoderma gangrenosum with adjunctive maggot debridement therapy. 62
36468819 2022
20
Treatment of pyoderma gangrenosum with apremilast monotherapy. 62
36345410 2022
21
Pyoderma Gangrenosum after COVID-19 Infection and Vaccination. 62
36442730 2022
22
Characterization of Legal Claims Involving Patients with Pyoderma Gangrenosum. 62
35895601 2022
23
Pyoderma Gangrenosum Affecting the Dorsal Hand: A Case Report. 62
36337430 2022
24
Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck: A retrospective study. 62
35151756 2022
25
[Development of spindle cell squamous cell carcinoma within a longstanding pyoderma gangrenosum]. 62
35471236 2022
26
Clinical efficacy of flap transplantation combined with vacuum sealing drainage and methylprednisolone and cyclosporine in the treatment of pyoderma gangrenosum. 62
36321334 2022
27
Peristomal granulation tissue mimicking peristomal pyoderma gangrenosum in the context of urine-diverting ostomies. 62
36186406 2022
28
A Rare Complication: Postoperative Pyoderma Gangrenosum in Segmental Colitis Associated With Diverticulosis. 62
36001403 2022
29
Pyoderma Gangrenosum. 62
36351270 2022
30
Juvenile gangrenous vasculitis of the scrotum: systematic review. 62
35323998 2022
31
Brocq's geometric phagedena over penis with keloidal scars. 62
36220799 2022
32
Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum. 62
36004431 2022
33
Pyoderma Gangrenosum Triggered by COVID-19 Vaccination in a Patient with Ulcerative Colitis: A Case Report. 62
36426538 2022
34
A case with prediagnosis of soft tissue infection who finally diagnosed as pyoderma gangrenosum of ulcerative colitis. 62
36412491 2022
35
Skin Manifestations in Patients with Selective Immunoglobulin E Deficiency. 62
36431272 2022
36
Novel and Off-Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. 62
36434425 2022
37
Limb amputation in patients with pyoderma gangrenosum: a multi-institutional case series. 62
36446938 2022
38
Clinical characteristics of peristomal pyoderma gangrenosum: A Single Center Retrospective Observational Study. 62
35789032 2022
39
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome associated with pyoderma gangrenosum: report of two patients. 62
36345566 2022
40
A Rare Form of Granulomatosis With Polyangiitis With Pyoderma Gangrenosum. 62
36407211 2022
41
Abscess-like skin and lung lesions in a patient with acute lymphoblastic leukemia: Pyoderma gangrenosum. 62
35278042 2022
42
Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis. 62
36097621 2022
43
Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. 62
35946554 2022
44
The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. 62
36305958 2022
45
Off-label uses of ustekinumab. 62
36208443 2022
46
Aseptic Abscess Syndrome With Ulcerative Colitis and Pyoderma Gangrenosum. 62
35643412 2022
47
An unusual presentation of celiac disease in adult patient. 62
36245465 2022
48
Pyoderma gangrenosum-like ulcers over the face in a case of granulomatosis with polyangiitis. 62
36250767 2022
49
Postherpetic Trigeminal Trophic Syndrome: A Case Report. 62
36198630 2022
50
The role of interleukins 6, 8, 17 and 23 in the pathogenesis of pyoderma gangrenosum. 62
36268700 2022

Variations for Pyoderma Gangrenosum

Expression for Pyoderma Gangrenosum

Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 TNF MMP9 MMP1 IL1R1 IFNA2 CXCL8
2
Show member pathways
13.32 MMP9 MMP26 MMP10 MMP1 ITGB2 CXCL8
3
Show member pathways
13.17 TNF NOD2 MMP9 MMP1 ITGB2 IL1R1
4
Show member pathways
13.05 TNF SIGLEC5 PSTPIP1 NOD2 NLRP3 MMP9
5
Show member pathways
12.34 TNF NOD2 NLRP3 IL1R1 IFNA2 CXCL8
6
Show member pathways
12.21 TNF MMP9 MMP1 CXCL8 CSF3
7 11.93 TNF MMP9 IL1R1 CXCL8
8
Show member pathways
11.81 PSTPIP1 NOD2 NLRP3 MEFV
9 11.8 ITGB2 CXCL8 CCR6
10 11.75 CXCL8 ITGB2 MMP1 MMP9 TNF
11 11.71 TNF IL1R1 CCR6
12
Show member pathways
11.7 TNF NLRP3 F3
13
Show member pathways
11.65 TNF MMP9 MMP26 MMP10 MMP1
14 11.63 MMP9 MMP1 CXCL8
15 11.61 CSF3 CXCL8 MMP9 TNF
16
Show member pathways
11.6 CXCL8 MMP1 MMP9 TNF
17 11.56 MMP9 MMP10 MMP1 CXCL8
18 11.47 TNF NOD2 IFNA2 CXCL8
19 11.39 MEFV NLRP3 NOD2
20 11.38 TNF IL1R1 CXCL8 CSF3
21 11.37 MMP9 MMP1 CXCL8
22 11.3 MMP9 MMP1 CXCL8
23 11.23 TNF MMP1 CXCL8
24 11.23 TNF MMP9 MMP1 IFNA2 CXCL8
25 11.2 TNF MMP9 ITGB2
26 11.1 NLRP3 MMP9 IL1R1
27 10.9 TNF NLRP3 MMP9 CXCL8
28 10.62 MMP9 CHI3L1
29
Show member pathways
10.3 TNF CXCL8

GO Terms for Pyoderma Gangrenosum

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.81 MMP9 MMP26 MMP10 MMP1 CHI3L1
2 cell surface GO:0009986 9.77 TNF NOD2 ITGB2 IL1R1 F3 CCR6
3 extracellular region GO:0005576 9.7 APOH CHI3L1 CSF3 CXCL8 F3 IFNA2

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 10.14 CHI3L1 CSF3 F3 TNF
2 extracellular matrix organization GO:0030198 10.13 MMP1 MMP10 MMP26 MMP9 TNF
3 cellular response to lipopolysaccharide GO:0071222 10.11 TNF NOD2 NLRP3 CXCL8 CSF3
4 negative regulation of inflammatory response GO:0050728 10.09 NLRP3 MVK MMP26 MEFV
5 extracellular matrix disassembly GO:0022617 10.05 MMP9 MMP10 MMP1
6 regulation of inflammatory response GO:0050727 10.05 TNF NOD2 NLRP3 IL1R1
7 positive regulation of interleukin-8 production GO:0032757 10.01 TNF NOD2 F3 CHI3L1
8 positive regulation of interleukin-1 beta production GO:0032731 9.97 TNF NOD2 NLRP3 MEFV
9 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.87 TNF NOD2
10 positive regulation of type 2 immune response GO:0002830 9.86 NOD2 NLRP3
11 positive regulation of prostaglandin-E synthase activity GO:2000363 9.8 NOD2 ITGB2
12 cellular response to peptidoglycan GO:0071224 9.76 NOD2 NLRP3
13 leukocyte migration involved in inflammatory response GO:0002523 9.72 TNF ITGB2 CCR6
14 detection of biotic stimulus GO:0009595 9.65 NOD2 NLRP3
15 pattern recognition receptor signaling pathway GO:0002221 9.65 NOD2 NLRP3 MEFV
16 defense response GO:0006952 9.63 CXCL8 IFNA2 NLRP3 NOD2 TNF
17 inflammatory response GO:0006954 9.58 TNF PSTPIP1 NLRP3 MEFV ITGB2 IL1R1
18 collagen catabolic process GO:0030574 9.56 MMP9 MMP26 MMP10 MMP1
19 cellular extravasation GO:0045123 9.52 TNF ITGB2

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase activity GO:0004222 9.56 MMP9 MMP26 MMP10 MMP1
2 metallopeptidase activity GO:0008237 9.02 MMP9 MMP26 MMP10 MMP1

Sources for Pyoderma Gangrenosum

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....